Printer Friendly

Radiologists May Soon Use 3-D Printing to Develop Personalised Treatments.

M2 PHARMA-March 3, 2015-Radiologists May Soon Use 3-D Printing to Develop Personalised Treatments

(C)2015 M2 COMMUNICATIONS

3-D printing could become a powerful tool in customising interventional radiology treatments to individual patient needs, with clinicians having the ability to construct devices to a specific size and shape, according to a study being presented at the Society of Interventional Radiology's Annual Scientific Meeting.

Researchers and engineers collaborated to print catheters, stents and filaments that were bioactive, giving these devices the ability to deliver antibiotics and chemotherapeutic medications to a targeted area in cell cultures.

Using 3-D printing technology and resorbable bioplastics, D'Agostino and his team of biomedical engineers and nanosystem engineers at LSUH and Louisiana Tech University developed bioactive filaments, chemotherapy beads, and catheters and stents containing antibiotics or chemotherapeutic agents.

The team then tested these devices in cell cultures to see if they could inhibit growth of bacteria and cancer cells.

When testing antibiotic-containing catheters that could slowly release the drug, D'Agostino's team found that the devices inhibited bacterial growth. Researchers also saw that filaments carrying chemotherapeutic agents were able to inhibit the growth of cancer cells.

The research team is also able to print biodegradable filaments, catheters and stents that contain antibiotics and chemotherapeutic agents. These types of devices may help patients avoid the need to undergo a second procedure or treatment when conventional materials are used.

The Society of Interventional Radiology is a nonprofit, professional medical society representing more than 5,600 practicing interventional radiology physicians, scientists and clinical associates, dedicated to improving patient care through the potential of image-guided therapies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 3, 2015
Words:274
Previous Article:Johnson & Johnson announces plans to sell Cordis business to Cardinal Health.
Next Article:Kosaraju Named Finance Chief at Penumbra.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters